ReviewPLoS neglected tropical diseases2014
Immune regulation during chronic visceral leishmaniasis.
Review in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Integrative transcriptomics and hypothesis-driven transfer machine learning reveal conserved and species-specific host-parasite dynamics acrossFrontiers in cellular and infection microbiology · 2026Pooled it
- Cytotoxic CD4Parasite immunology · 2026Article
- Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy.Frontiers in microbiology · 2026Review
- Development of a High-Throughput Screening Platform and a Pathogenesis Model forInternational journal of molecular sciences · 2025Article
- Diagnostic potential of GLP recombinant antigens in whole blood assays for Leishmania infantum infection.Parasites & vectors · 2025Article
- Environmental change increases the transmission risk of visceral leishmaniasis in central China around the Taihang mountains.Environmental health : a global access science source · 2025Article
- Chemokines Signature and T Cell Dynamics in Leishmaniasis: Molecular insight and therapeutic application.Expert reviews in molecular medicine · 2024Review
- T-cell and Soluble Co-inhibitory Receptor Expression in Patients With Visceral Leishmaniasis Are Markers of Treatment Response and Clinical Outcome.Open forum infectious diseases · 2024Article
- Post-Kala-Azar Dermal Leishmaniasis.The American journal of tropical medicine and hygiene · 2024Article
- The role of CD4Frontiers in cellular and infection microbiology · 2024Review
- Potential Biomarkers for Asymptomatic Visceral Leishmaniasis among Iraq-Deployed U.S. Military Personnel.Pathogens (Basel, Switzerland) · 2023Article
- Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.Frontiers in immunology · 2023Review
- Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.Frontiers in medicine · 2023Review
- Expression Profile Analysis of Circular RNAs in Leishmaniasis.Tropical medicine and infectious disease · 2022Article
- T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis.Frontiers in immunology · 2022Review
- Article
- Antileishmanial Drug Discovery and Development: Time to Reset the Model?Microorganisms · 2021Review
- The Inflammatory Effects of Dietary Lipids Regulate Growth of Parasites during Visceral Leishmaniasis.mSphere · 2021Article
- Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.PLoS neglected tropical diseases · 2021Article
- Hematological Changes in Dogs with Visceral Leishmaniasis Are Associated with Increased IFN-γ and TNF Gene Expression Levels in the Bone Marrow.Microorganisms · 2021Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis is a chronic parasitic disease associated with severe immune dysfunction. Treatment options are limited to relatively toxic drugs, and there is no vaccine for humans available. Hence, there is an urgent need to better understand immune responses following infection with Leishmania species by studying animal models of disease and clinical samples from patients. Here, we review recent discoveries in these areas and highlight shortcomings in our knowledge that need to be addressed if better treatment options are to be developed and effective vaccines designed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.